Johnson & Johnson (JNJ), AstraZeneca plc (ADR) (AZN), The Procter & Gamble Company (PG): The Priceless Health Business Every Investor Overlooks

Page 1 of 2

Investors know Johnson & Johnson (NYSE:JNJ) for many things.

It’s arguably health care’s biggest name. The company’s pharmaceutical segment boasts billions of dollars in sales annually from its largest drug, immunology star Remicade, alone. It has a number of up-and-coming drugs ready to fuel the company’s future, and the firm’s orthopedics device division isn’t looking too bad recently, either, with the acquisition of medical device producer Synthes last year.

Yet many investors often forget about Johnson & Johnson (NYSE:JNJ)’s powerhouse consumer health business. It’s a business that demands your attention, however: With the volatile nature of health care today, strong consumer sales just might be Johnson & Johnson’s reliable foundation.

Johnson & Johnson (JNJ)

Grit, not glamour

Compared to J&J’s two other major businesses, its consumer health segment might not seem like much. It only posted sales of around $7.3 billion over the first half of the year. That’s a sizable sum to be sure, but it was only just over half of what the company’s medical device business sold in that same time span.

Compared to both devices and pharmaceuticals, consumer products also grew slowly. Sales for the segment climbed only 1.6% year-over-year over 2013′s first six months, far below the 9.9% and 11% from medical devices and pharmaceuticals, respectively.

So, why is this segment important to Johnson & Johnson (NYSE:JNJ) and its investors? Take a look inside its medical device and pharmaceuticals sales, and you’ll see that not every product or drug is hitting high marks for growth. Generic drug competition has torn down top neuroscience drug Concerta’s sales by more than 16% in the year’s first half.

While many of J&J’s drugs are showing strong growth, a quick look around the company’s big pharma rivals shows just how hard the patent cliff has hammered firms’ sales. AstraZeneca plc (ADR) (NYSE:AZN), one of big pharma’s top companies, saw sales decline by more than 15% last year with patent expirations hammering both the company’s top and bottom lines. As more drugs fall off patent in the near future, AstraZeneca plc (ADR) (NYSE:AZN)’s outlook remains murky – and its stock’s in a state of flux. While big pharma can mean big profits, the industry’s boom-or-bust nature can lead to serious investor disappointment.

Volatility doesn’t end with pharmaceuticals, either. J&J’s medical device segment might have grown strongly, but without its Synthes acquisition, the division’s performance so far this year hasn’t been quite as illustrious as a first glance might have suggested. Three of the division’s top five specialties by sales saw revenue fall over the year’s first half, part of a slowdown that’s affected many of the device industry’s leaders.

Adding stable growth

Up-and-down sales are the nature of health care, but that’s the beauty of Johnson & Johnson (NYSE:JNJ)’s consumer segment: It’s the cash cow that investors can count on. While growth may be elusive, this segment — accounting for more than 20% of the company’s overall revenue — is a reliable, if not glamorous, revenue producer.

It’s a trend symptomatic to the consumer health industry: Rival The Procter & Gamble Company (NYSE:PG)‘s health care division, a consumer-focused business, has posted 3% sales growth in each of the last three years, emerging as the conglomerate’s most reliable business in a time when other, higher-selling segments have seen revenue fall recently.

Consumer sales aren’t geographically exclusive, either: Johnson & Johnson (NYSE:JNJ)’s division posted similar growth in both the U.S. and internationally over the first six months of the year. This business likely won’t become an emerging market superstar, but as middle classes develop in growing economies such as India and Latin America, Johnson & Johnson is well-positioned to take advantage of basic health needs of consumers in such developing nations.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!